EN – Secondary listing Euronext Paris starts 7 July 2014, name change to ESPERITE N.V

June 30, 2014 Financial Reports, Group News

Cryo-Save Group N.V.

Secondary listing Euronext Paris starts 7 July 2014, name change to Esperite N.V scheduled for 2 July 2014

Zutphen, the Netherlands – 30 June 2014

Cryo-Save Group N.V. (Euronext: CRYO, ‘Cryo-Save’, or ‘the Group’), the leading international stem cell processing and cryo-conservation company and the largest family stem cell bank in Europe announces today that its secondary listing on Euronext Paris shall become effective 7 July 2014 and that in relation to the secondary listing a summary document has been published today and is available on the company’s website – www.cryo-save.com/group.

The company’s shareholders are expected to approve the change of the company’s formal name to Esperite N.V. during an extraordinary general meeting of shareholders to be held on 2 July 2014. The company clearly stated its strategy and ambition to become an important predictive and regenerative medicine promoter. The secondary listing on Euronext Paris will become effective and dealings in the company’s shares will commence on Euronext Paris, at 9:00 a.m. (Paris time) on 7 July 2014, under the symbol ticker symbol “ESP” and ISIN Code NL0009272137. The company’s primary listing on Euronext Amsterdam will continue and will act synergistically with the Euronext Paris listing, adding to the visibility of the Group. The company is not offering any new shares nor any other securities in connection with the Euronext Paris listing.

Euronext Paris is currently the most active trading platform for public life sciences companies in Europe. The company considers the secondary Euronext Paris listing as a clear signal of its ambitions in the


Cryo-Save Group + 31 (0) 575 548 998
Frederic Amar, CEO
About Cryo-Save (www.cryo-save.com/group)

Cryo-Save, the leading international family stem cell bank, stores more than 260,000 samples from umbilical cord blood and cord tissue. There are already many diseases treatable by the use of stem cells, and the number of treatments will only increase. Cryo-Save has cryopreserved samples from over 70 countries on six continents, with ultra-modern processing and storage facilities in Belgium, Switzerland, Dubai, South Africa and Portugal.

Related Articles